Canada’s Blind Spot on Drug Safety in Pregnancy – SOGC
The Society of Obstetricians and Gynaecologists of Canada (SOGC) shared a post on LinkedIn:
“A new op-ed published in the Montreal Gazette, co-authored by SOGC CEO Dr. Diane Francoeur and SOGC member Prof. Anick Bérard, highlights a critical gap in women’s health: the lack of robust data on the safety of medications during pregnancy.
Dr. Francoeur and Prof. Bérard note that most prescription drugs approved in Canada lack adequate safety data for use in pregnancy, leaving patients and physicians to make important decisions without clear evidence.
They call for stronger national data infrastructure, sustained investment in women’s health research and better integration of real-world evidence to change behaviour and improve outcomes.
Read the full op-ed.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 23, 2026, 07:33Michel Zelaquett: Ultra-Minimally Invasive Treatment for Uterine Fibroids
-
Apr 23, 2026, 07:29Asma Khalil: Highlights From Fetal Therapy 2026 in Warsaw
-
Apr 23, 2026, 07:24Christopher Robinson: Management of Immediate and Delayed PPT with Cesarean Delivery
-
Apr 23, 2026, 07:17The True Scale and Impact of Early Pregnancy Loss – Fertility Plus
-
Apr 22, 2026, 13:13Kate Devine: SREI Advances REI Fellowship Training with Updated Learning Objectives
-
Apr 22, 2026, 13:07Vinesh Gadhia: India Takes the Stage at World AI in Fertility Conference 2026
-
Apr 22, 2026, 11:36Christopher Robinson: Vaginal Clamping of Uterine Arteries in Postpartum Hemorrhage
-
Apr 22, 2026, 11:25Naval Shah: IVF Lab Quality and Standardisation Take Centre Stage at ALPHA 2026
-
Apr 22, 2026, 11:09Khalil Faaed: Recent Updates in AI Are Advancing Embryology and ART